Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Clinical variables through the protocol

From: Physical activity as a predictor of fremanezumab response in chronic migraine – the Phy-Fre-Mig study

Variable

Baseline

T1m

T3m

FDR – adjusted P value

HDM (median, IQR)

23 [17–29]

16 [11–24]

11 [7–22]

p < 0.001

MDM (median, IQR)

15 [10–19]

9 [4–14]

5 [3–10]

p < 0.001

MIH (median, IQR)

7 [5.9–7.8]

6 [5-7.5]

6 [4.6–7.1]

p < 0.001

ADM (median, IQR)

15 [9–22]

11 [2–16]

7 [2–14]

p < 0.001

TDM (median, IQR)

9 [3–13]

4 [1–9]

2 [1–5]

p < 0.001

MOH (Percentage)

81.6%

43.4%

27.6%

p < 0.001

  1. HDM: Headache days per month; MDM: migraine days per month (MDM); MIH: median intensity of headache; ADM: NSAIDs and acetaminophen days per month; TDM: triptan days per month
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us